ABSTRACT
increased by 36% globally [1] . The majority of the increase occurred in rapidly developing countries, and the United States ranked third in the world for total antimicrobial consumption [1] . As a result of these practices, there has been a marked increase in multidrug-resistant (MDR) pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and extended spectrum beta-lactamase-producing organisms (ESBL) [2] .
These resistant isolates are no longer limited to health care settings, but in recent years have emerged in the community [2] . Consequently, the World Health Organization and US Centers for Disease Control and Prevention (CDC) have identified antimicrobial resistance as a serious public health threat [3] .
Infections from resistant organisms are associated with poor patient outcomes with increased morbidity and mortality [4] . The management of resistant infections also contributes to rising health care costs [4] .
Furthermore, the rate of eroding antimicrobial susceptibility patterns has outpaced the rate of novel antimicrobial drug discovery. In response to an impending post-antibiotic era, physician Dale Gerding introduced the concept of antimicrobial stewardship programs (ASP). The overarching goals for ASP include optimizing antimicrobial therapy to enhance patient safety, reduce inappropriate antimicrobial use, and preventing antimicrobial resistance. Two core strategies were developed, forming the foundation for ASP. Prospective audit with intervention and feedback involves interaction and feedback between an infectious diseases (ID) physician/pharmacist and the ordering prescriber at the point of order entry [5] .
Formulary restriction and preauthorization establish minimum requirements for antimicrobial utilization. These standards are often developed based on local susceptibility patterns, safety issues, concern for secondary infections, and affordability (inpatient and outpatient). In conjunction with supportive strategies (i.e., education, decision support services, treatment algorithms), these core strategies ensure a robust ASP presence. The literature contains substantial evidence on the efficacy of these strategies leading to the development of an endorsed ASP guideline and inclusion with the National Action Plan [5, 37] .
Despite fewer data on ASP implementation in other health care settings, ASP efforts should expand across the care continuum, including the emergency department (ED). An estimated 142,000 ED visits occur annually secondary to adverse events associated with antimicrobial therapy, emphasizing the need for ASP in this fast-paced environment [6] . The three most common infections encountered in the ED are respiratory tract, skin and soft tissue, and urinary tract infections (UTIs) [6] . These common infections are managed in both inand outpatient settings, and ED practitioners are involved with establishing empiric and definitive treatment. As health care legislation continues to evolve, ED practitioners will be expected to expand ASP by promoting Appropriately, May and colleagues [7] brought attention to ASP implementation in the ED with a call to action and concept paper published in 2012. The purpose of this paper is to summarize the existing literature on various ED-based ASP processes, with a focus on managing three commonly encountered infections. Please note this review is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
ASSESSMENT OF ED CAPACITY FOR ASP IMPLEMENTATION
Identification of potential barriers to successful implementation remains a crucial first step for any new ASP. Inherent to the emergent nature in the ED, challenges are characterized by high turnover rates for both patients and practitioners. The majority (67%) of triaged ED patients waited\1 h to be seen by a practitioner [8] . The remaining one-third (35%) of patients spent between 2 and 4 h from triage to discharge or admission [8] 
POTENTIAL STRATEGIES FOR ASP IMPLEMENTATION IN THE ED
The following are general antimicrobial stewardship strategies that transcend across settings, but can be applied to commonly encountered scenarios in the ED. A combination of these strategies is most effective for developing robust ASP services in the ED.
Key Players on the ASP ''Dream Team''
Successful ASP implementation in the ED depends on gaining support from key opinion leaders in the emergency medicine department and administrative leaders in the organization. recommendations are critical to this process [12, 13] . In particular, this applies to discharged patients for whom culture data may not result until 72-96 h post-discharge, often observed in cases of UTIs. This process decreased the time between positive culture review and time to follow-up with the patient or primary care provider, if indicated [13] . Furthermore, a multidisciplinary approach to culture follow-up has also been associated with a decrease in return ED visits within 72 h and hospital readmissions within 30 days [14] . More than 25% patients required post-discharge interventions, primarily because of pathogen non-susceptibility [14] . This study emphasizes the importance of appropriate antimicrobial selection while patients are housed in the ED.
Culture follow-up also allows the ED to take ownership of the care provided to their patients.
Technological Assistance for ASP
The field of rapid diagnostics largely impacts ID management for admitted patients [15] . Direct testing from specimen versus culture-based testing minimizes turnaround times for organism identification and antimicrobial susceptibility information. Rapid diagnostics has the potential to minimize empiric use of broad-spectrum antimicrobials, thereby allowing for a thoughtful and targeted approach to antimicrobial selection. One of the benefits and the role of rapid molecular diagnostics in the ED are the immediate results provided by point-of-care tests (POCT). Examples include rapid streptococcal antigen tests and respiratory viral panels. Risk assessment combined with POCT may enable ED practitioners to initiate more directed, narrow-spectrum antimicrobial therapy. POCT can also guide appropriate antimicrobial selection for discharge of less serious infections that do not require admission. These tests may reduce overall antibiotic use and facilitate earlier changes in antibiotic regimens for certain infections [16] . Despite and institutional-specific recommendations [7] . With federal mandates on EHR implementation, CDS is an area with potential growth and high impact for ASP interventions.
Prior to broad implementation of EHR, effective CDS programs have been associated with 12-14% reduction in antimicrobial prescriptions [40] .
ED-Specific Information
Antimicrobial order forms or order sets, clinical pathways, and an ED-specific antibiogram, if feasible, are examples of resources that may assist ED prescribers during their decision-making process [7] .
Order forms and sets are intended to guide a prescriber at the point of electronic order entry. Potential messages that appear with an order may include best practice alerts (BPA), criteria for use with restricted agents, and associated monitoring parameters for specific drugs. 
ED MANAGEMENT APPROACHES FOR THREE COMMON INFECTIONS
Respiratory tract, skin and soft tissue, and urinary tract are the three most common infections encountered in the ED [6] .
Therefore, it is important to highlight potential treatment strategies and opportunities for stewardship initiatives for these three infections. Medical Care Survey data. ARTIs account for nearly 12% of all ambulatory care visits annually [17] . Nasopharyngitis, bronchitis or bronchiolitis, viral pneumonia, and influenza were identified as not requiring antibiotics.
Acute Respiratory Tract Infections
Expectedly, the use of antibiotics in viral illnesses has not been shown to improve patient outcomes. However, more than half (61%) of ARTI cases with viral etiologies inappropriately received an antibiotic [17] .
Further, Kronman et al. [39] estimated bacterial prevalence to be 27.4% among common ARTIs. When assessing antimicrobial prescribing frequencies, health care providers may have inadvertently prescribed 11.4 million antimicrobial courses. These data highlight the need for integrating strategies that minimize overtreatment (i.e., watch-and-wait strategies, contingency antimicrobial prescriptions, or rapid diagnostics tools).
Ong et al. [18] [38] identified a reduction in ancillary testing (i.e., cultures, chest radiographs) and antibiotic prescriptions when integrating rapid influenza testing into practice. In contrast, there was a significant increase in anti-influenza therapy.
These data highlight the potential for identifying causative organisms associated with RTI and minimize overtreatment. In addition to rapid diagnostics and bedside scoring tools, several studies report the use of procalcitonin (PCT) to differentiate between infectious versus noninfectious inflammatory conditions [20] . PCT is a precursor peptide to the hormone calcitonin. It becomes acutely elevated in bacterial infections, but rapidly decreases during clinical recovery [15] .
Compared with other inflammatory
biomarkers, PCT has demonstrated superior diagnostic accuracy when compared to C-reactive protein [21, 22] . The interest in utilizing PCT to guide antibiotic therapy has been evaluated for both ARTI and sepsis across multiple care settings. Schuetz et al. [23] performed a meta-analysis examining the safety of PCT algorithms to guide antibiotic initiation and treatment duration in patients with ARTI across multiple care settings. The authors concluded that PCT algorithms effectively reduced overall antibiotic exposure in patients by 50%, from 8 to 4 days. They did not observe an increase in mortality or treatment failure rates. Additionally, the use of PCT in the ED differentiated congestive heart failure versus ARTI resulted in a reduction in adverse events and antimicrobial consumption [24] . Studies supporting the use of PCT in other ARTI include chronic obstructive pulmonary disease exacerbations and CAP [25] [26] [27] . Consistent with data from the meta-analysis, these studies highlighted a reduction in antibiotic exposure. Challenges to widespread implementation of PCT-based algorithms may include the cost and logistical workflow. However, incorporation of PCT testing in the ED may be an effective strategy to reduce antimicrobial misuse for ARTI.
Skin and Soft Tissue Infections
Despite evolving terminology for skin and soft tissue infections (SSTI) throughout the years, the incidence has risen in the past decade [6] . The spread of community-acquired MRSA (CA-MRSA) infections may have contributed to the rise along with increases in resource utilization [28] . An analysis of ED prescribing patterns for skin infections conducted between the years 2007 and 2010 revealed a stable rate of ED visits, but noted an increasing rate of anti-CA-MRSA antibiotics for skin infections [28] . Furthermore, patients were frequently either overtreated with combination therapy for cellulitis (included agents active against CA-MRSA) or received unnecessary therapy following incision and drainage (I&D) of uncomplicated abscesses. In contrast, when antimicrobial therapy was warranted for the treatment of purulent cellulitis, 16% of patients failed to receive therapy active against CA-MRSA. These findings highlight the importance of proper wound classification and risk stratification in patients with acute bacterial skin and skin structure infections (ABSSSIs). Current recommendations for skin and skin structure infections from the Infectious Diseases Society of America (IDSA) suggest that skin abscesses do not require antibiotic treatment post successful I&D [29] . The guidelines also recommend the use of agents effective against streptococci for nonpurulent cellulitis.
However, these recommendations are rarely integrated into clinical practice, and patients are often overtreated for simpler skin infections [28] . Another situation that supports the need for an ED-based ASP service is the frivolous administration of vancomycin in the ED.
Mueller et al. [30] reported in their single-center study that 68% of patients received one-time doses of vancomycin prior to discharge, whereby 73% of these patients were under-dosed with \15 mg per kg of body weight. This study highlights the real possibility of developing resistance if these prescribing behaviors are not addressed. Unfortunately, these patients typically present to the ED or another ambulatory clinic as their initial point of entry into the health care system, yet the 2014 IDSA update did not address management issues specific to the ED.
Appropriately, a best practice guideline for the management of skin infections has been outlined specifically for ED practitioners [31] .
The treatment approach is to risk stratify based on disease severity and ensure patients receive appropriate levels of care (e.g., emergent surgical interventions for severe sepsis and necrotizing fasciitis).
For low-risk patients who can be managed in an outpatient setting, the best practice guideline divided the group into nonpurulent versus purulent cellulitis [31] 
Urinary Tract Infections
Similar to skin infections, the use of broad-spectrum antimicrobials extends to UTI treatment as well. IDSA guidelines state that asymptomatic bacteriuria (ASB) does not require antibiotic treatment [32] . UTI diagnosis based on a urinalysis (UA) or dipstick alone in the absence of symptoms leads to overuse of antibiotics [33] . Often observed in clinical practice, empiric UTI treatment with a broad-spectrum agent such as a fluoroquinolone is frequently initiated based on an improperly collected UA in the ED. Pallin et al. [33] reported that 58% of patients failed to receive instructions on urine sample collection, resulting in only 6% of patients performing the correct midstream, clean-catch technique. In addition, according to current guidelines, if local resistance rates for fluoroquinolone exceed 10% for common uropathogens such as Escherichia coli, then oral agents such as ciprofloxacin and levofloxacin are no longer recommended for empiric uncomplicated UTI treatment [34] 
